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Since the initial publication of the review article [1], a
number of readers have contacted us to clarify potential
erroneous information in the article. These comments
focused on our review of the use of transcranial magnetic
stimulation (TMS) for treatment-resistant depression
(TRD). In the initial article, we concluded that TMS is
well-tolerated and has been approved by the FDA for
adults who have failed to respond to one antidepressant,
but that its use in TRD was not yet supported by rigorous
double-blind randomized clinical trials. It should be noted,
that for the article, we searched PubMed and based our
review on the several meta-analyses we found during this
search.
1. The NIH-sponsored large multicenter trial [2] was
published in 2010, not 2009. Also, note that the
primary outcome measure of this study was
remission, not response (as was the case in the
Neuronetics study [3]). Most important, we
erroneously reported that most remitters had low
antidepressant resistance. In fact, the relationship
between remission and treatment resistance was not
significant. Also, the study cohort had an average of
1.5 failed research-quality adequate treatment trials
(by Antidepressant Treatment History Form [ATHF]
criteria), which translates approximately to 3 to 6
clinical medication trials, in the current episode and
an average of 3.3 failed research-quality adequate
treatment trials (approximately 9 clinical attempts)
during their lifetimes. In conclusion, the data from
George et al. [2] support the efficacy of TMS for
TRD.
2. We were also provided a link (http://www.effective-
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from the Agency for Healthcare Research and Quality
(a division of the US Department of Health and
Human Services) website that was not identified
during our PubMed search. This review of primary
data found that TMS demonstrates greater efficacy
than sham control for TRD and found no statistically
significant differences in depression severity and
response rate in published studies directly comparing
TMS to ECT.
We appreciate these comments from the readers and
concur that, contrary to what is stated in our initial article,
that there is substantial evidence supporting the efficacy
of TMS for TRD.
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